학술논문
Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study
Document Type
article
Author
Freiberg, Matthew S; Chang, Chung-Chou H; Skanderson, Melissa; Patterson, Olga V; DuVall, Scott L; Brandt, Cynthia A; So-Armah, Kaku A; Vasan, Ramachandran S; Oursler, Kris Ann; Gottdiener, John; Gottlieb, Stephen; Leaf, David; Rodriguez-Barradas, Maria; Tracy, Russell P; Gibert, Cynthia L; Rimland, David; Bedimo, Roger J; Brown, Sheldon T; Goetz, Matthew Bidwell; Warner, Alberta; Crothers, Kristina; Tindle, Hilary A; Alcorn, Charles; Bachmann, Justin M; Justice, Amy C; Butt, Adeel A
Source
JAMA Cardiology. 2(5)
Subject
Language
Abstract
ImportanceWith improved survival, heart failure (HF) has become a major complication for individuals with human immunodeficiency virus (HIV) infection. It is unclear if this risk extends to different types of HF in the antiretroviral therapy (ART) era. Determining whether HIV infection is associated with HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), or both is critical because HF types differ with respect to underlying mechanism, treatment, and prognosis.ObjectivesTo investigate whether HIV infection increases the risk of future HFrEF and HFpEF and to assess if this risk varies by sociodemographic and HIV-specific factors.Design, setting, and participantsThis study evaluated 98 015 participants without baseline cardiovascular disease from the Veterans Aging Cohort Study, an observational cohort of HIV-infected veterans and uninfected veterans matched by age, sex, race/ethnicity, and clinical site, enrolled on or after April 1, 2003, and followed up through September 30, 2012. The dates of the analysis were October 2015 to November 2016.ExposureHuman immunodeficiency virus infection.Main outcomes and measuresOutcomes included HFpEF (EF≥50%), borderline HFpEF (EF 40%-49%), HFrEF (EF